EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Position Increased by Woodline Partners LP

Woodline Partners LP increased its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 25.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 501,724 shares of the company's stock after acquiring an additional 101,724 shares during the quarter. Woodline Partners LP owned approximately 0.74% of EyePoint Pharmaceuticals worth $3,738,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Suvretta Capital Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 31.1% in the 4th quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock worth $50,534,000 after purchasing an additional 1,607,268 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in EyePoint Pharmaceuticals by 51.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after buying an additional 1,958,580 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 3.1% during the fourth quarter. Franklin Resources Inc. now owns 4,137,567 shares of the company's stock valued at $30,825,000 after acquiring an additional 125,519 shares during the period. Vanguard Group Inc. grew its position in shares of EyePoint Pharmaceuticals by 24.8% during the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock worth $28,334,000 after acquiring an additional 755,045 shares during the last quarter. Finally, Federated Hermes Inc. grew its position in shares of EyePoint Pharmaceuticals by 92.7% during the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after acquiring an additional 1,783,765 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Stock Up 18.1%

EYPT traded up $1.08 during trading on Wednesday, reaching $7.04. The stock had a trading volume of 2,529,079 shares, compared to its average volume of 825,268. The stock has a 50 day moving average of $5.81 and a two-hundred day moving average of $7.04. The firm has a market capitalization of $484.43 million, a price-to-earnings ratio of -3.52 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a 1-year low of $3.91 and a 1-year high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, hitting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $24.50 million for the quarter, compared to the consensus estimate of $8.84 million. On average, research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Chardan Capital decreased their target price on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Mizuho decreased their price objective on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a report on Friday, May 16th. Wall Street Zen upgraded EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $25.38.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.